Impact of Atrial Fibrillation Ablation on Recurrent Hospitalization: A Nationwide Cohort Study.


Journal

JACC. Clinical electrophysiology
ISSN: 2405-5018
Titre abrégé: JACC Clin Electrophysiol
Pays: United States
ID NLM: 101656995

Informations de publication

Date de publication:
03 2019
Historique:
received: 23 07 2018
revised: 28 09 2018
accepted: 25 10 2018
entrez: 23 3 2019
pubmed: 23 3 2019
medline: 3 4 2020
Statut: ppublish

Résumé

This study assessed the impact of atrial fibrillation (AF) ablation on hospitalization and antiarrhythmic drug use in the community setting. Despite the widespread increase in the use of catheter ablation to treat AF in the United States, the impact of ablation on arrhythmic, cardiovascular, and noncardiovascular hospitalizations remains unclear. The national prospectively acquired Truven Health MarketScan data set (January 1, 2008 to December 31, 2014) was used to identify patients who underwent first time AF ablation with uninterrupted enrollment for 24 months (12 months pre-ablation and 12 months post-ablation). Multivariate logistic regression was used to determine predictors of hospitalization. Of 5,238 patients who underwent AF ablation for the first time, 2,720 patients with uninterrupted enrollment were analyzed (age 60 ± 10 years; 29% were women, 79% had hypertension, and 23% had heart failure [HF]). AF ablation was associated with significantly reduced all-cause hospitalization from 1,669 hospitalizations in the year before ablation to 1,034 hospitalizations in the year after ablation, which was driven primarily by a 56% reduction in arrhythmic hospitalization. Nonarrhythmic cardiovascular hospitalizations also declined through a 43% drop off in HF hospitalizations. Noncardiovascular hospitalization rates did not significantly change. Age younger than 55 years (odds ratio [OR]: 1.43; p < 0.001), obstructive sleep apnea (OR: 1.38; p < 0.001), and HF (OR: 1.29; p = 0.024) were multivariate predictors for decreased arrhythmic hospitalization. Rates of antiarrhythmic drug use also significantly declined post-procedure by 37.5% (p < 0.001). In this nationwide cohort, AF ablation was associated with significant decreases in arrhythmic and nonarrhythmic cardiovascular hospitalizations, which was driven by reductions in hospitalization for AF and HF.

Sections du résumé

OBJECTIVES
This study assessed the impact of atrial fibrillation (AF) ablation on hospitalization and antiarrhythmic drug use in the community setting.
BACKGROUND
Despite the widespread increase in the use of catheter ablation to treat AF in the United States, the impact of ablation on arrhythmic, cardiovascular, and noncardiovascular hospitalizations remains unclear.
METHODS
The national prospectively acquired Truven Health MarketScan data set (January 1, 2008 to December 31, 2014) was used to identify patients who underwent first time AF ablation with uninterrupted enrollment for 24 months (12 months pre-ablation and 12 months post-ablation). Multivariate logistic regression was used to determine predictors of hospitalization.
RESULTS
Of 5,238 patients who underwent AF ablation for the first time, 2,720 patients with uninterrupted enrollment were analyzed (age 60 ± 10 years; 29% were women, 79% had hypertension, and 23% had heart failure [HF]). AF ablation was associated with significantly reduced all-cause hospitalization from 1,669 hospitalizations in the year before ablation to 1,034 hospitalizations in the year after ablation, which was driven primarily by a 56% reduction in arrhythmic hospitalization. Nonarrhythmic cardiovascular hospitalizations also declined through a 43% drop off in HF hospitalizations. Noncardiovascular hospitalization rates did not significantly change. Age younger than 55 years (odds ratio [OR]: 1.43; p < 0.001), obstructive sleep apnea (OR: 1.38; p < 0.001), and HF (OR: 1.29; p = 0.024) were multivariate predictors for decreased arrhythmic hospitalization. Rates of antiarrhythmic drug use also significantly declined post-procedure by 37.5% (p < 0.001).
CONCLUSIONS
In this nationwide cohort, AF ablation was associated with significant decreases in arrhythmic and nonarrhythmic cardiovascular hospitalizations, which was driven by reductions in hospitalization for AF and HF.

Identifiants

pubmed: 30898236
pii: S2405-500X(18)30875-2
doi: 10.1016/j.jacep.2018.10.015
pii:
doi:

Substances chimiques

Anti-Arrhythmia Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

330-339

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Jia Guo (J)

Center for Arrhythmia Care, Heart and Vascular Center, The University of Chicago Pritzker School of Medicine, The University of Chicago Medicine, Chicago, Illinois.

Hemal M Nayak (HM)

Center for Arrhythmia Care, Heart and Vascular Center, The University of Chicago Pritzker School of Medicine, The University of Chicago Medicine, Chicago, Illinois.

Stephanie A Besser (SA)

Center for Arrhythmia Care, Heart and Vascular Center, The University of Chicago Pritzker School of Medicine, The University of Chicago Medicine, Chicago, Illinois.

Andrew Beaser (A)

Center for Arrhythmia Care, Heart and Vascular Center, The University of Chicago Pritzker School of Medicine, The University of Chicago Medicine, Chicago, Illinois.

Zaid Aziz (Z)

Center for Arrhythmia Care, Heart and Vascular Center, The University of Chicago Pritzker School of Medicine, The University of Chicago Medicine, Chicago, Illinois.

Michael Broman (M)

Center for Arrhythmia Care, Heart and Vascular Center, The University of Chicago Pritzker School of Medicine, The University of Chicago Medicine, Chicago, Illinois.

Cevher Ozcan (C)

Center for Arrhythmia Care, Heart and Vascular Center, The University of Chicago Pritzker School of Medicine, The University of Chicago Medicine, Chicago, Illinois.

Roderick Tung (R)

Center for Arrhythmia Care, Heart and Vascular Center, The University of Chicago Pritzker School of Medicine, The University of Chicago Medicine, Chicago, Illinois.

Gaurav A Upadhyay (GA)

Center for Arrhythmia Care, Heart and Vascular Center, The University of Chicago Pritzker School of Medicine, The University of Chicago Medicine, Chicago, Illinois. Electronic address: upadhyay@uchicago.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH